Switch theme
Sign up to access all valuation multiples
Akeso Inc is an investment holding company. The Company’s subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation, and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in USA.
2019
2.8K+
LTM Revenue $377M
LTM EBITDA -$24.9M
$9.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Akeso has a last 12-month revenue of $377M and a last 12-month EBITDA of -$24.9M.
In the most recent fiscal year, Akeso achieved revenue of $582M and an EBITDA of $279M.
Akeso expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Akeso valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $108M | $582M | XXX | XXX | XXX |
| Gross Profit | $25.0M | $95.6M | XXX | XXX | XXX |
| Gross Margin | 23% | 16% | XXX | XXX | XXX |
| EBITDA | -$164M | $279M | XXX | XXX | XXX |
| EBITDA Margin | -152% | 48% | XXX | XXX | XXX |
| Net Profit | -$138M | -$150M | XXX | XXX | XXX |
| Net Margin | -128% | -26% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Akeso's stock price is HKD 87 (or $11).
Akeso has current market cap of HKD 78.0B (or $10.0B), and EV of HKD 74.4B (or $9.6B).
See Akeso trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.6B | $10.0B | XXX | XXX | XXX | XXX | $-0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Akeso has market cap of $10.0B and EV of $9.6B.
Akeso's trades at 27.2x LTM EV/Revenue multiple, and -411.6x LTM EBITDA.
Analysts estimate Akeso's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Akeso and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $9.6B | XXX | XXX | XXX |
| EV/Revenue | 16.4x | XXX | XXX | XXX |
| EV/EBITDA | 34.3x | XXX | XXX | XXX |
| P/E | 38.5x | XXX | XXX | XXX |
| P/E/Growth | -1.3x | XXX | XXX | XXX |
| EV/FCF | 46.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAkeso's NTM/LTM revenue growth is 63%
Akeso's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Akeso's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Akeso's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Akeso and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 440% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 48% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -271% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 111% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 20% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 28% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 49% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Akeso acquired XXX companies to date.
Last acquisition by Akeso was XXXXXXXX, XXXXX XXXXX XXXXXX . Akeso acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Akeso founded? | Akeso was founded in 2019. |
| Where is Akeso headquartered? | Akeso is headquartered in Hong Kong. |
| How many employees does Akeso have? | As of today, Akeso has 2.8K+ employees. |
| Who is the CEO of Akeso? | Akeso's CEO is Dr. Yu Xia. |
| Is Akeso publicy listed? | Yes, Akeso is a public company listed on HKG. |
| What is the stock symbol of Akeso? | Akeso trades under 09926 ticker. |
| When did Akeso go public? | Akeso went public in 2020. |
| Who are competitors of Akeso? | Similar companies to Akeso include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Akeso? | Akeso's current market cap is $10.0B |
| What is the current revenue of Akeso? | Akeso's last 12-month revenue is $377M. |
| What is the current EBITDA of Akeso? | Akeso's last 12-month EBITDA is -$24.9M. |
| What is the current EV/Revenue multiple of Akeso? | Current revenue multiple of Akeso is 27.2x. |
| What is the current EV/EBITDA multiple of Akeso? | Current EBITDA multiple of Akeso is -411.6x. |
| What is the current revenue growth of Akeso? | Akeso revenue growth between 2023 and 2024 was 440%. |
| Is Akeso profitable? | Yes, Akeso is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
